Novation Awards Medline with National Med/Surg Products Distribution Agreement
Medline Industries, Inc. announced today that Novation, a leading healthcare supply chain expertise and contracting company for the members of VHA Inc., UHC, and Provista LLC, awarded the leading healthcare supplier with a new national medical-surgical products distribution agreement.
In the five-year agreement, which is effective September 1, Medline will help Novation drive cost savings and efficiencies to the more than 65,000 members of VHA Inc. and UHC, two national healthcare alliances, and Provista, LLC, including hospitals, surgery centers, long-term care facilities, physician offices, clinics and other non-acute care facilities. Medline will distribute both national branded products as well as its broad array of Medline brand medical and surgical products, to the healthcare facilities from its 34 distribution centers throughout the country.
Were pleased to receive this agreement and are committed to providing the members Novation serves with outstanding value and effective distribution services to help drive efficiencies in their supply chain, says Scott Simonson, vice president of national accounts for Medline.  Â
Managerial Challenges: Setting Boundaries and Priorities in the Workplace
May 3rd 2024Maintaining boundaries can be challenging in a culture of overwork. In this installment of Dear Helpdesk, learn how to communicate effectively with your boss, prioritize your values, and safeguard your work-life balance.
Comprehensive Guide to Lymphedema: Causes, Prevention, and Management Strategies
May 3rd 2024Lymphedema, a chronic condition often stemming from cancer treatments, leads to tissue swelling. Early detection through surveillance programs and proper skincare can prevent complications like infections.
Advancing Viral Disease Treatment of Recurrent Genital Herpes, Hepatitis B and D Viruses
May 2nd 2024Health care has an unmet need for the treatment of herpesviruses, hepatitis B, and hepatitis D, which would enhance patient outcomes. What should be done, and what challenges do companies that are trying to develop treatments face?
